Cencora, Inc. (NYSE:COR) Shares Acquired by Foster & Motley Inc.

Foster & Motley Inc. lifted its position in shares of Cencora, Inc. (NYSE:COR) by 1.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,593 shares of the company’s stock after purchasing an additional 135 shares during the period. Foster & Motley Inc.’s holdings in Cencora were worth $1,709,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD acquired a new stake in shares of Cencora during the first quarter worth about $2,183,619,000. JPMorgan Chase & Co. acquired a new stake in shares of Cencora during the first quarter worth about $1,199,695,000. Boston Partners acquired a new stake in shares of Cencora during the first quarter worth about $1,001,269,000. Capital Research Global Investors acquired a new stake in shares of Cencora during the first quarter worth about $650,424,000. Finally, Bessemer Group Inc. acquired a new stake in shares of Cencora during the first quarter worth about $556,245,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on COR shares. Leerink Partners dropped their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Wells Fargo & Company boosted their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Robert W. Baird dropped their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. Finally, JPMorgan Chase & Co. boosted their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $259.44.

Cencora Price Performance

Shares of COR opened at $245.38 on Thursday. Cencora, Inc. has a twelve month low of $191.11 and a twelve month high of $247.66. The stock’s 50 day moving average is $231.57 and its two-hundred day moving average is $230.64. The firm has a market capitalization of $48.35 billion, a PE ratio of 26.64, a P/E/G ratio of 1.49 and a beta of 0.44. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.80% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.